Long-term response with the atypical reaction to nivolumab in microsatellite stability metastatic colorectal cancer: A case report
| Autor: | Nataliya Babyshkina, Nataliya Popova, Evgeny Grigoryev, Tatyana Dronova, Polina Gervas, Alexey Dobrodeev, Dmitry Kostromitskiy, Victor Goldberg, Sergei Afanasiev, Nadejda Cherdyntseva |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Drug Target Insights, Vol 18, Iss 1 (2024) |
| Druh dokumentu: | article |
| ISSN: | 1177-3928 17462045 |
| DOI: | 10.33393/dti.2024.2637 |
| Popis: | Immunotherapy has become an integral part of a comprehensive treatment approach to metastatic colorectal cancer (mCRC). Nivolumab (Opdivo) is a human immunoglobulin G4 monoclonal antibody that blocks the interaction between the programmed cell death 1 (PD-1) receptor and its ligands 1/2 (PD-L1/PD-L2), leading to inhibition of T-cell proliferation, cytokine secretion, and enhanced immune response. The US Food and Drug Administration (FDA) has approved this drug for use in high microsatellite instability (MSI-high)/deficiencies in mismatch repair (dMMR) advanced CRC patients. However, its efficacy is extremely limited in microsatellite stability (MSS)/mismatch repair proficient (pMMR) patients. We report a case of a 42-year-old man diagnosed with MSS/pMMR mCRC who has achieved a durable response to nivolumab after a progression under chemotherapy with antiangiogenic treatment. We observed for the first time an atypical response after 8 months of nivolumab treatment, with the regression of previous primary pulmonary lesions and the presence of new para-aortic lymph node lesions. This report demonstrates that a subset of pretreated mCRC patients with the MSS/pMMR phenotype may benefit from nivolumab and these patients need more attention. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|